Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
envafolimab + lenvatinib + paclitaxel-albumin
- Development stage
- Unknown
- Lead developer
- 3D Medicines
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Oral, Intravenous
01
Overview
Envafolimab + lenvatinib + paclitaxel-albumin is an investigational combination regimen comprising three agents with distinct mechanisms of action, studied primarily in advanced solid tumors such as gastric/gastroesophageal junction adenocarcinoma. Envafolimab is a subcutaneously administered humanized single-domain anti–PD-L1 monoclonal antibody that blocks the interaction between PD-L1 and its receptor, restoring T-cell mediated antitumor immunity. Lenvatinib is an oral small molecule tyrosine kinase inhibitor targeting multiple receptors including VEGFR, FGFR, PDGFRα, RET, and KIT to inhibit tumor angiogenesis and proliferation. Paclitaxel-albumin (nab-paclitaxel) is a nanoparticle formulation of the microtubule-stabilizing chemotherapeutic agent paclitaxel bound to human serum albumin for improved solubility and delivery. This combination aims to synergistically enhance antitumor efficacy by integrating immune checkpoint inhibition, antiangiogenic therapy, and cytotoxic chemotherapy[1][2][7].
- Brand names
- Abraxane
- Other names
- albumin-bound paclitaxel
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)TUBB (Tubulin (alpha and beta subunits))PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)CD274 (Programmed cell death protein 1 ligand 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on envafolimab + lenvatinib + paclitaxel-albumin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on envafolimab + lenvatinib + paclitaxel-albumin.